Header Logo

Connection

JOSEPH JANKOVIC to Tourette Syndrome

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Tourette Syndrome.
JOSEPH JANKOVIC
Connection Strength
18.894
Tourette Syndrome
  1. Axial tics in Tourette syndrome and chronic tic disorders. J Neurol. 2024 Nov; 271(11):7232-7238.
    View in: PubMed
    Score: 0.833
  2. An update on the pharmacological management of Tourette syndrome and emerging treatment paradigms. Expert Rev Neurother. 2024 Oct; 24(10):1025-1033.
    View in: PubMed
    Score: 0.823
  3. Tics emergencies and malignant tourette syndrome: Assessment and management. Neurosci Biobehav Rev. 2024 Apr; 159:105609.
    View in: PubMed
    Score: 0.802
  4. Real-world experience with VMAT2 inhibitors in Tourette syndrome. J Neurol. 2023 Sep; 270(9):4518-4522.
    View in: PubMed
    Score: 0.762
  5. Contrasting features between Tourette syndrome and secondary tic disorders. J Neural Transm (Vienna). 2023 07; 130(7):931-936.
    View in: PubMed
    Score: 0.756
  6. Oromandibular tics associated with Tourette syndrome. J Neurol. 2023 May; 270(5):2591-2596.
    View in: PubMed
    Score: 0.743
  7. Dystonic motor and phonic tics in Tourette syndrome. J Neurol. 2022 Oct; 269(10):5312-5318.
    View in: PubMed
    Score: 0.707
  8. The clinical phenomenology and correlations of oculogyric tics. Acta Neurol Belg. 2022 Aug; 122(4):925-930.
    View in: PubMed
    Score: 0.703
  9. Self-injurious behavior in Tourette syndrome. J Neurol. 2022 May; 269(5):2453-2459.
    View in: PubMed
    Score: 0.678
  10. Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 10 01; 4(10):e2128204.
    View in: PubMed
    Score: 0.678
  11. Beyond tics: movement disorders in patients with Tourette syndrome. J Neural Transm (Vienna). 2021 08; 128(8):1177-1183.
    View in: PubMed
    Score: 0.669
  12. Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics. 2020 10; 17(4):1681-1693.
    View in: PubMed
    Score: 0.632
  13. Treatment of tics associated with Tourette syndrome. J Neural Transm (Vienna). 2020 05; 127(5):843-850.
    View in: PubMed
    Score: 0.602
  14. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
    View in: PubMed
    Score: 0.566
  15. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014 Jan; 29(1):126-30.
    View in: PubMed
    Score: 0.391
  16. The genetics of Tourette syndrome. Nat Rev Neurol. 2012 Mar 13; 8(4):203-13.
    View in: PubMed
    Score: 0.350
  17. Tourette syndrome: evolving concepts. Mov Disord. 2011 May; 26(6):1149-56.
    View in: PubMed
    Score: 0.328
  18. Tourette's syndrome in adults. Mov Disord. 2010 Oct 15; 25(13):2171-5.
    View in: PubMed
    Score: 0.317
  19. Motor-phonic tic mimicking essential palatal myoclonus. Mov Disord. 2009 Oct 15; 24(13):2030-2.
    View in: PubMed
    Score: 0.296
  20. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):70-3.
    View in: PubMed
    Score: 0.293
  21. Mozart's movements and behaviour: a case of Tourette's syndrome? Postgrad Med J. 2008 Jun; 84(992):313-7.
    View in: PubMed
    Score: 0.269
  22. Mozart's movements and behaviour: a case of Tourette's syndrome? J Neurol Neurosurg Psychiatry. 2007 Nov; 78(11):1171-5.
    View in: PubMed
    Score: 0.258
  23. Malignant Tourette syndrome. Mov Disord. 2007 Sep 15; 22(12):1743-50.
    View in: PubMed
    Score: 0.256
  24. GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology. 2007 Jan 09; 68(2):159-60.
    View in: PubMed
    Score: 0.244
  25. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand. 2006 Dec; 114(6):400-2.
    View in: PubMed
    Score: 0.242
  26. Effect of vagal nerve stimulation in a case of Tourette's syndrome and complex partial epilepsy. Mov Disord. 2006 Aug; 21(8):1273-5.
    View in: PubMed
    Score: 0.237
  27. Tourette's syndrome and the law. J Neuropsychiatry Clin Neurosci. 2006; 18(1):86-95.
    View in: PubMed
    Score: 0.227
  28. Tics associated with other disorders. Adv Neurol. 2006; 99:61-8.
    View in: PubMed
    Score: 0.227
  29. Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs. 2005 May; 10(2):365-80.
    View in: PubMed
    Score: 0.217
  30. Secondary tics and tourettism. Braz J Psychiatry. 2005 Mar; 27(1):11-7.
    View in: PubMed
    Score: 0.217
  31. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003 Dec; 18(12):1530-3.
    View in: PubMed
    Score: 0.197
  32. Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003 Nov; 60(11):1595-8.
    View in: PubMed
    Score: 0.196
  33. Tourettism and dystonia after subcortical stroke. Mov Disord. 2002 Jul; 17(4):821-5.
    View in: PubMed
    Score: 0.178
  34. Tourette's syndrome. N Engl J Med. 2001 Oct 18; 345(16):1184-92.
    View in: PubMed
    Score: 0.170
  35. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 10 01; 4(10):e2129397.
    View in: PubMed
    Score: 0.169
  36. Synaptic processes and immune-related pathways implicated in Tourette syndrome. Transl Psychiatry. 2021 01 18; 11(1):56.
    View in: PubMed
    Score: 0.161
  37. Differential diagnosis and etiology of tics. Adv Neurol. 2001; 85:15-29.
    View in: PubMed
    Score: 0.161
  38. Botulinum toxin in the treatment of tics. Arch Neurol. 2000 Aug; 57(8):1190-3.
    View in: PubMed
    Score: 0.156
  39. Bilineal transmission in Tourette syndrome. Neurology. 1999 Sep 11; 53(4):813-8.
    View in: PubMed
    Score: 0.147
  40. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019 05 07; 92(19):896-906.
    View in: PubMed
    Score: 0.143
  41. Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019 05 07; 92(19):907-915.
    View in: PubMed
    Score: 0.143
  42. Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. Am J Psychiatry. 2019 03 01; 176(3):217-227.
    View in: PubMed
    Score: 0.142
  43. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord. 2018 08; 33(8):1272-1280.
    View in: PubMed
    Score: 0.137
  44. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018 04; 78(5):525-541.
    View in: PubMed
    Score: 0.133
  45. [Tics and Tourette's syndrome]. Cas Lek Cesk. 1997 Jun 26; 136(13):399-404.
    View in: PubMed
    Score: 0.126
  46. Tourette syndrome. Phenomenology and classification of tics. Neurol Clin. 1997 May; 15(2):267-75.
    View in: PubMed
    Score: 0.125
  47. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord. 1996 Sep; 11(5):563-6.
    View in: PubMed
    Score: 0.119
  48. Tourettism associated with Huntington's disease. Mov Disord. 1995 Jan; 10(1):103-5.
    View in: PubMed
    Score: 0.106
  49. Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry. 2015 Jan; 172(1):82-93.
    View in: PubMed
    Score: 0.105
  50. Copy number variation in obsessive-compulsive disorder and tourette syndrome: a cross-disorder study. J Am Acad Child Adolesc Psychiatry. 2014 Aug; 53(8):910-9.
    View in: PubMed
    Score: 0.102
  51. Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994 May; 9(3):347-9.
    View in: PubMed
    Score: 0.101
  52. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet. 2013 Oct; 9(10):e1003864.
    View in: PubMed
    Score: 0.098
  53. Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol. 1993 Mar; 50(3):286-8.
    View in: PubMed
    Score: 0.093
  54. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013 Feb; 28(2):210-5.
    View in: PubMed
    Score: 0.092
  55. Mutation screening of the HTR2B gene in patients with Tourette syndrome. Neurosci Lett. 2012 Sep 27; 526(2):150-3.
    View in: PubMed
    Score: 0.090
  56. Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg. 2012; 90(4):213-24.
    View in: PubMed
    Score: 0.089
  57. Diagnosis and classification of tics and Tourette syndrome. Adv Neurol. 1992; 58:7-14.
    View in: PubMed
    Score: 0.086
  58. The coexistence of tics and dystonia. Arch Neurol. 1991 Aug; 48(8):862-5.
    View in: PubMed
    Score: 0.084
  59. Dystonic tics in patients with Tourette's syndrome. Mov Disord. 1991; 6(3):248-52.
    View in: PubMed
    Score: 0.080
  60. The association of Tourette syndrome and dopa-responsive dystonia. Mov Disord. 2011 Feb 01; 26(2):359-60.
    View in: PubMed
    Score: 0.080
  61. Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord. 2010 Dec; 16(10):628-38.
    View in: PubMed
    Score: 0.078
  62. Coprophenomena in Tourette syndrome. Dev Med Child Neurol. 2009 Mar; 51(3):218-27.
    View in: PubMed
    Score: 0.070
  63. Tardive dystonia in patients with Tourette's syndrome. Mov Disord. 1988; 3(3):274-80.
    View in: PubMed
    Score: 0.065
  64. Orofacial and other self-mutilations. Adv Neurol. 1988; 49:365-81.
    View in: PubMed
    Score: 0.065
  65. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci. 1987 Aug; 14(3 Suppl):541-6.
    View in: PubMed
    Score: 0.063
  66. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2006 Nov; 21(11):1831-8.
    View in: PubMed
    Score: 0.060
  67. Botulinum toxin in dermatology - beyond wrinkles and sweat. J Cosmet Dermatol. 2006 Jun; 5(2):169.
    View in: PubMed
    Score: 0.059
  68. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006 Apr; 3(2):192-206.
    View in: PubMed
    Score: 0.058
  69. Essential tremor among children. Pediatrics. 2004 Nov; 114(5):1203-5.
    View in: PubMed
    Score: 0.052
  70. Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov Disord. 2004 Oct; 19(10):1237-8.
    View in: PubMed
    Score: 0.052
  71. Screening for mutations in the MECP2 (Rett syndrome) gene in Gilles de la Tourette syndrome. Arch Neurol. 2003 Apr; 60(4):502-3.
    View in: PubMed
    Score: 0.047
  72. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord. 1996 Jul; 11(4):431-3.
    View in: PubMed
    Score: 0.029
  73. Cocaine-related movement disorders. Mov Disord. 1993 Apr; 8(2):175-8.
    View in: PubMed
    Score: 0.023
  74. 9p monosomy in a patient with Gilles de la Tourette's syndrome. Neurology. 1991 Sep; 41(9):1513-5.
    View in: PubMed
    Score: 0.021
  75. The phenomenology of tics. Mov Disord. 1986; 1(1):17-26.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.